Selected article for: "protective equipment and SARS testing"

Author: Wolfgruber, Stella; Loibner, Martina; Puff, Markus; Melischnig, Alexander; Zatloukal, Kurt
Title: SARS-CoV2 neutralizing activity of ozone on porous and non-porous materials
  • Cord-id: 4bcbdeky
  • Document date: 2022_1_25
  • ID: 4bcbdeky
    Snippet: The COVID-19 pandemic has generated a major need for non-destructive and environmentally friendly disinfection methods. This work presents the development and testing of a disinfection process based on gaseous ozone for SARS-CoV-2-contaminated porous and non-porous surfaces. A newly developed disinfection chamber was used, equipped with a CeraPlasâ„¢ cold plasma generator that produces ozone during plasma ignition. A reduction of more than log 6 of infectious virus could be demonstrated for viru
    Document: The COVID-19 pandemic has generated a major need for non-destructive and environmentally friendly disinfection methods. This work presents the development and testing of a disinfection process based on gaseous ozone for SARS-CoV-2-contaminated porous and non-porous surfaces. A newly developed disinfection chamber was used, equipped with a CeraPlas™ cold plasma generator that produces ozone during plasma ignition. A reduction of more than log 6 of infectious virus could be demonstrated for virus-contaminated cotton and FFP3 face masks as well as glass slides after exposure to 800 ppm ozone for 10−60 min, depending on the material. In contrast to other disinfectants, ozone can be produced quickly and cost-effectively, and its environmentally friendly breakdown product oxygen does not leave harmful residues. Disinfection with ozone could help to overcome delivery difficulties of personal protective equipment by enabling safe reuse with further applications, thereby reducing waste generation, and may allow regular disinfection of personal items with non-porous surfaces.

    Search related documents:
    Co phrase search for related documents
    • long term exposure and lung cancer: 1, 2, 3
    • lung cancer and mab monoclonal antibody: 1, 2